Agree it’s great to get a really deep dive into things.
so hard to translate that via asx announcements, the RnD day was the next best thing but even that ran out of time a little.
there’s a lot to digest but off the bat one of the interesting aspects about the 008 trial is that it’s multi pronged. Above the DMOAD, label and pricing aspects, the extras for me were
- bio markers and DMOAD are required for TGA provisional (ie. a step change over current treatments).
and
- a look through to the P3 results (002) as it will be placebo controlled and have many of the same endpoints. Will give partners huge confidence in the P3 results and commensurate uplift in value of deal. Very clever to configure this to have 008 readout while 002 still ongoing so I presume a deal is on the cards after 008 readout and before 002 readout?
really need to listen to the whole thing over again.
some very deep content therein.
- Forums
- ASX - By Stock
- PAR
- Interview with Paul Rennie and Capital 51
Interview with Paul Rennie and Capital 51, page-13
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
24.5¢ | 24.5¢ | 24.5¢ | $1K | 4.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4166 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 5492 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4166 | 0.245 |
7 | 79126 | 0.240 |
7 | 114610 | 0.235 |
9 | 155290 | 0.230 |
11 | 212234 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 5492 | 3 |
0.255 | 81349 | 8 |
0.260 | 108149 | 4 |
0.265 | 1800 | 1 |
0.270 | 20000 | 2 |
Last trade - 10.07am 02/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online